News Gilead presses go on first Nurix protein degrader drug Opt-in for IRAK4 drug comes after a Kymera/Sanofi candidate showed early activity in trials.
News Double blow for Sangamo as Novartis, Biogen exit deals The two deals for gene-modifying candidates were worth up to $3.1 billion including milestones.
News Mersana stung by FDA hold on STING drug Death in ph1 trial casts a pall over GSK-backed project, licensed for $100m upfront last year.
News Lilly adds to non-opioid pain pipeline with Confo deal Deal covers an AT2R inhibitor, a class that has been plagued by safety and efficacy issues.
News Morphic loses second partner as J&J exits integrin alliance Morphic Therapeutic has lost Johnson & Johnson's Janssen Pharma as a partner, following the termination of an alliance to develop drugs targeting integrins first agreed in 2019.
News Digital health investors getting choosier as sector matures Despite the well-documented retreat from record levels of funding for digital health ven
News Europe is facing a surge in STIs, says ECDC Cases of sexually-transmitted infections (STIs) – particularly gonorrhoea and syphilis – are at record levels across 29 European countries.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
